OK HB2546

Moves pseudoephedrine products from Schedule V to Schedule III of controlled dangerous substances, with exemptions for liquid, liquid capsule, and gel capsule formulations that contain other active ingredients.

Deletes prior regulations requiring pharmacy monitoring, tracking, and reporting of pseudoephedrine sales to consumers, including identification checks and daily purchase limits.

Removes the real-time electronic logbook requirement for nonprescription pseudoephedrine products and associated Oklahoma Bureau of Narcotics reporting rules.

Maintains reporting requirements for Schedule II-V controlled substances dispensed by prescription to the central repository within 24 hours, but eliminates specific pseudoephedrine monitoring provisions.

Effective date: November 1, 2012.